pharma · Ulcerative Colitis · Multiple Myeloma
AbbVie Deutschland GmbH
AbbVie Deutschland GmbH & Co. KG
APONTIS PHARMA Deutschland is a pharma organization headquartered in Wiesbaden, DE. Primary therapeutic focus areas include Ulcerative Colitis, Multiple Myeloma, Neovascular age-related macular degeneration, Psoriatic Ar
Wiesbaden, DE HQ
2018 Founded
101 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Wiesbaden, DE
- Founded
- 2018
- Employees
- 101
- Programs
- 102
- Drugs
- 119
- Patents
- 23
M22-128
Phase 3 · small molecule · Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
M22-128 for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) is a Phase 3 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Internal code M22-128
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- AbbVie Deutschland GmbH & Co. KG
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- active
- Trials
- 1